Interestingly, GDC-0449 treatment markedly inhibited expressions of Hedgehog receptors, including Patched-1, Patched-2 and smoothened. Furthermore, Bcl-2 was down-regulated following the treatment of GDC-0449 in glioma cells. Here, BCL2 is linked to central nervous system cancer.